TRKA (A608D)

NTRK1 · Variant type: point · HGVS: p.A608D

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Entrectinib	99.0%	0.9%	93.69
2	Pralsetinib	98.7%	1.3%	93.43
3	Alpelisib	97.7%	2.3%	97.22
4	Ripretinib	96.8%	3.2%	92.95
5	Repotrectinib	96.6%	3.4%	84.21
6	Crizotinib	96.1%	3.9%	91.39
7	Ponatinib	95.7%	4.3%	78.23
8	Nintedanib	91.4%	8.6%	90.23
9	Tivozanib	91.0%	9.0%	92.42
10	Cabozantinib	89.2%	10.8%	92.73
11	Pacritinib	88.6%	11.4%	88.64
12	Gilteritinib	87.6%	12.4%	88.97
13	Sunitinib	75.1%	24.9%	91.73
14	Tenalisib	74.1%	25.9%	97.98
15	Bosutinib	71.9%	28.1%	87.22
16	Defactinib	57.9%	42.1%	92.68
17	Apatinib	53.4%	46.6%	97.73
18	Umbralisib	48.1%	51.9%	98.74
19	Lorlatinib	45.3%	54.7%	97.24
20	Sorafenib	44.2%	55.8%	96.72
21	Regorafenib	39.0%	61.0%	95.99
22	Upadacitinib	37.0%	63.0%	97.98
23	Darovasertib	33.0%	67.0%	96.99
24	Fedratinib	26.6%	73.4%	96.21
25	Alectinib	25.9%	74.1%	95.49

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Entrectinib	99.0%	99.0%	+0.0%
Pralsetinib	98.7%	98.7%	+0.0%
Alpelisib	97.7%	97.5%	+0.2%
Ripretinib	96.8%	93.6%	+3.3%
Repotrectinib	96.6%	98.9%	-2.3%
Crizotinib	96.1%	95.8%	+0.3%
Ponatinib	95.7%	98.4%	-2.7%
Nintedanib	91.4%	93.8%	-2.4%
Tivozanib	91.0%	85.7%	+5.4%
Cabozantinib	89.2%	93.6%	-4.4%
Pacritinib	88.6%	89.4%	-0.8%
Gilteritinib	87.6%	92.6%	-5.1%
Sunitinib	75.1%	82.8%	-7.7%
Tenalisib	74.1%	59.0%	+15.0%
Bosutinib	71.9%	67.0%	+5.0%
Defactinib	57.9%	80.3%	-22.5%
Apatinib	53.4%	—	—
Umbralisib	48.1%	—	—
Lorlatinib	45.3%	63.2%	-17.9%
Sorafenib	44.2%	—	—
Regorafenib	39.0%	—	—
Upadacitinib	37.0%	—	—
Darovasertib	33.0%	—	—
Fedratinib	26.6%	56.2%	-29.6%
Alectinib	25.9%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.0ms